Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
about
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
P2860
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effectiveness and Safety of Om ...... der Routine Clinical Practice.
@en
type
label
Effectiveness and Safety of Om ...... der Routine Clinical Practice.
@en
prefLabel
Effectiveness and Safety of Om ...... der Routine Clinical Practice.
@en
P2093
P2860
P50
P356
P1476
Effectiveness and Safety of Om ...... der Routine Clinical Practice.
@en
P2093
Almudena Ribed
Ana Herranz
Ana Lorenzo-Pinto
Camino Sarobe Gonzalez
Carmen Guadalupe Rodriguez-Gonzalez
Cecilia M Fernandez-Llamazares
Elena Lallana Sainz
Elena Lobato Matilla
Esther Chamorro-de-Vega
Maria Sanjurjo
P2860
P304
P356
10.1177/1060028016659306
P407
P577
2016-07-14T00:00:00Z